. Author manuscript; available in PMC: 2018 Jan 29.

Published in final edited form as: J Osteoporos Phys Act. 2017 Nov 28;5(4):210. doi: 10.4172/2329-9509.1000210

Table 2.

22 week treatment effects on DXA-acquired regional BMD and biomarkers of bone turnover (Adjusted for Baseline Values of the Outcome and Gender) (Note: aBMD: areal Bone Mineral Density; OC: Osteocalcin; BALP: Bone Specific Alkaline Phosphatase; P1NP: Procollagen Type 1 N-Terminal Propeptide; CTX: C-Terminal Telopeptide of Type 1 Collagen).

	Diet only	Diet+Vest	p-value
	Mean (95% CI)	Mean (95% CI)	p-value
Δ DXA-acquired aBMD (mg/cm²)
Total Hip	−18.7 (−29.3, −8.1)	−6.1 (−15.7, 3.5)	0.08
Femoral Neck	−9.8 (−23.3, 3.7)	−11.9 (−24.1, 0.3)	0.82
Lumbar Spine	22.9 (7.7, 38.0)	13.7 (−0.2, 27.5)	0.37
Δ Biomarkers of Bone Turnover
OC (ng/mL)	−0.07 (−4.89, 4.76)	0.63 (−3.77, 5.03)	0.83
BALP (μg/L)	−0.70 (−1.70, 0.31)	0.59 (−0.33, 1.50)	0.07
P1NP (ng/mL)	−0.24 (−0.71, 0.24)	−0.06 (−0.47, 0.35)	0.57
CTX (ng/mL)	−0.11 (−0.45, 0.23)	−0.03 (−0.33, 0.27)	0.73